An open label single arm descriptive study to evaluate the efficacy and safety of irinotecan (cpt-11) plus cisplatin as chemotherapy for persistent and recurrent cervical carcinoma.
- Author:
Renee Vina G SICAM
;
Efren J DOMINGO
;
Jericho Thaddeus P LUNA
- Publication Type:Journal Article, Original
- Keywords:
IrinotecanCpt-11ChemotherapyCervical CarcinomaOpen Label Single Arm Descriptive Study
- MeSH:
Cisplatin;
Drug Therapy;
Uterine Cervical Neoplasms
- From:
Philippine Journal of Obstetrics and Gynecology
2007;31(4):203-211
- CountryPhilippines
- Language:English
-
Abstract:
Patients with cervical carcinoma who have failed first-line treatment with chemoradiation have combination chemotherapy to look into for progression-free and overall survivals. Objective: To determine the efficacy and safety of combination therapy of CPT-11 and cisplatin for persistent and recurrent cervical cancer. Methods: A retrospective review of medical records of persistent or recurrent cervical cancer patients who received treatment with Irinotecan (CPT-11) and Cisplatin combination was conducted in UP-PGH Cancer Institute CPT-11 60mg/m2 was administered on Days 1, 8 & 15. Cisplatin 60 mg/m2 was administered on Day 1 only. This cycle was repeated every 4 weeks. Active follow-up included physical and pelvic examinations, laboratory tests and evaluation of adverse experiences. Results: The study was performed in a total of 21 patients (age range: 35-69 years). The histologic types were squamous cell carcinoma, adenocarcinoma and adenosqamous carcinoma. Complete clinical response was achieved in 4 patients (19%). Anemia and diarrhea were the most common grade 3-4 side effects. Conclusion: The combination of CPT-11 and Cisplatin shows moderate activity with acceptable toxicity in the treatment of persistent and recurrent cervical carcinoma. (Author)
